二甲双胍与癌症:真实世界证据失败后的解决之道
本文回顾了二甲双胍作为抗癌药物从2005年观察性研究到随机试验的历程。早期观察性研究报告癌症发病率降低,但2012年发现其受时间相关偏倚影响而夸大获益;避免偏倚的观察性研究未发现关联,随机试验亦未发现癌症发病率或结局改善,包括纳入3649例女性、随访5年的最大3期乳腺癌辅助治疗试验。作者提出采用模拟随机试验的严谨观察性设计可避免这些偏倚。
要点
- 早期观察性研究显示二甲双胍降低癌症发病率,但受时间相关偏倚影响而夸大获益。
- 避免偏倚的观察性研究未发现二甲双胍与癌症的关联,随机试验亦未显示获益。
- 最大3期乳腺癌辅助治疗试验(3649例,随访5年)未发现二甲双胍改善无病生存或总生存。
核心结论
- 观察性真实世界证据在正确评估二甲双胍对癌症发病率和结局的影响方面遭遇重大失败,原因在于可预防的偏倚,且这些偏倚在2022年仍很突出。
研究设计与样本
- 本文为综述,检索范围未明确报告,汇总了实验研究、观察性研究和随机临床试验。
主要发现
- 实验研究显示二甲双胍通过多种途径具有抗癌作用,可能抑制癌细胞增殖。
- 多项非随机观察性研究报告二甲双胍使用者的癌症发病率和结局显著降低,但2012年发现这些研究受时间相关偏倚(如永恒时间偏倚)影响,倾向于大幅夸大药物获益。
- 避免这些偏倚的观察性研究未发现关联。
- 二甲双胍治疗2型糖尿病和作为各种晚期或转移性癌症辅助治疗的随机试验未发现癌症发病率或结局降低。
- 最大的3期随机试验(二甲双胍作为乳腺癌辅助治疗,纳入3649例女性,随访5年)未发现二甲双胍改善无病生存或总生存。
关键数值与推荐
- 最大3期随机试验纳入3649例女性,随访5年,未发现二甲双胍对无病生存或总生存的获益。
- 避免偏倚的观察性研究未发现二甲双胍与癌症的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The quest to repurpose metformin, an antidiabetes drug, as an agent for cancer prevention and treatment, which began in 2005 with an observational study that reported a reduction in cancer incidence among metformin users, generated extensive experimental, observational, and clinical research. Experimental studies revealed that metformin has anticancer effects via various pathways, potentially inhibiting cancer cell proliferation. Concurrently, multiple nonrandomized observational studies reported remarkable reductions in cancer incidence and outcomes with metformin use. However, these studies were shown, in 2012, to be affected by time-related biases, such as immortal time bias, which tend to greatly exaggerate the benefit of a drug. The observational studies that avoided these biases did not find an association. Subsequently, the randomized trials of metformin for the treatment of type 2 diabetes and as adjuvant therapy for the treatment of various cancers, advanced or metastatic, did not find reductions in cancer incidence or outcomes. Most recently, the largest phase 3 randomized trial of metformin as adjuvant therapy for breast cancer, which enrolled 3,649 women with a 5-year follow-up, found no benefit for disease-free survival or overall survival with metformin. This major failure of observational real-world evidence studies in correctly assessing the effects of metformin on cancer incidence and outcomes was caused by preventable biases which, surprisingly, are still prominent in 2022. Rigorous approaches for observational studies that emulate randomized trials, such as the incident and prevalent new-user designs along with propensity scores, avoid these biases and can provide more accurate real-world evidence for the repurposing of drugs such as metformin.
引用
- Yu OHY, Suissa S. Metformin and Cancer: Solutions to a Real-World Evidence Failure. Diabetes Care. 2023. PMID: 37185680. doi:10.2337/dci22-0047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。